New schizophrenia drug KarXT checked for risky drug interactions
NCT ID NCT07118215
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing whether KarXT, a new drug for schizophrenia, changes how the body processes three other common medications (midazolam, fexofenadine, and digoxin). Sixty healthy adults will take KarXT along with each of these drugs to see if their levels in the blood are affected. The goal is to identify any potential drug interactions before KarXT is used more widely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KarXT (a combination of xanomeline and trospium chloride)
What this could lead to
If successful, this study will show whether KarXT can be safely taken with other common medications without changing their effects.
What could go wrong
This is an early phase 1 study in only 60 healthy volunteers, not patients. It only measures drug levels, not real-world safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
ICON - Lenexa
RECRUITINGLenexa, Kansas, 66219-9746, United States
Contact Phone: •••-•••-••••